Mary C. Birmingham
- Pharmacology top 0.2%
- Infectious Diseases top 1%
- Epidemiology top 2%
- Cardiology and Cardiovascular Medicine top 2%
- Clinical Biochemistry top 0.2%
- Co-authors
- Jerome J. SchentagAlan ForrestDavid E. NixCharles H. BallowThomas F. GossAlison MeagherCraig R. RaynerPamela A. Moise-Broder
- Topics
- Antibiotics Pharmacokinetics and Efficacy (13 papers)Antimicrobial Resistance in Staphylococcus (9 papers)Pneumonia and Respiratory Infections (7 papers)
- Partner nations
- United StatesAustraliaDenmark
In The Last Decade
Mary C. Birmingham
32 papers receiving 4.1k citations
Hit Papers
Peers
Comparison fields: 5 of 119
- Pharmacology 2.0k
- Infectious Diseases 1.4k
- Epidemiology 1.2k
- Cardiology and Cardiovascular Medicine 1.1k
- Clinical Biochemistry 935
Countries citing papers authored by Mary C. Birmingham
This map shows the geographic impact of Mary C. Birmingham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary C. Birmingham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary C. Birmingham more than expected).
Fields of papers citing papers by Mary C. Birmingham
This network shows the impact of papers produced by Mary C. Birmingham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary C. Birmingham. The network helps show where Mary C. Birmingham may publish in the future.
Co-authorship network of co-authors of Mary C. Birmingham
This figure shows the co-authorship network connecting the top 25 collaborators of Mary C. Birmingham. A scholar is included among the top collaborators of Mary C. Birmingham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary C. Birmingham. Mary C. Birmingham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 15 | |
| 2 | 4 | |
| 3 | The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trialbreakdown → | 158 |
| 4 | 22 | |
| 5 | 11 | |
| 6 | Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCIbreakdown → | 942 |
| 7 | 15 | |
| 8 | Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infectionsbreakdown → | 589 |
| 9 | 97 | |
| 10 | 56 | |
| 11 | 244 | |
| 12 | 324 | |
| 13 | 170 | |
| 14 | 129 | |
| 15 | 50 | |
| 16 | 114 | |
| 17 | 12 | |
| 18 | 18 | |
| 19 | 18 | |
| 20 | 53 |
About Mary C. Birmingham
Mary C. Birmingham is a scholar working on Applied Microbiology and Biotechnology, Microbiology and Molecular Medicine, having authored 32 papers that have together received 4.3k indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (13 papers), Antimicrobial Resistance in Staphylococcus (9 papers) and Pneumonia and Respiratory Infections (7 papers). The work is most often cited by research in Microbiology (152 citations), Applied Microbiology and Biotechnology (389 citations) and Molecular Medicine (925 citations). Mary C. Birmingham has collaborated with scholars based in United States, Australia and Denmark. Frequent co-authors include Jerome J. Schentag, Alan Forrest, David E. Nix, Charles H. Ballow, Thomas F. Goss, Alison Meagher, Craig R. Rayner, Pamela A. Moise-Broder, Paul Burton and Juliana Ianus. Their work appears in journals such as New England Journal of Medicine, Circulation and Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.